Movicol Go (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Macrogol 3350)

Movicol Go, an osmotic laxative, is used to manage conditions where stool softening and increased intestinal water are required.

• Constipation: softens stool and facilitates regular bowel movements in acute or chronic cases.
• Chronic idiopathic constipation: provides sustained osmotic activity to maintain stool hydration over long‑term therapy.
• Opioid‑induced constipation: counteracts opioid‑related reduction in gut motility by drawing water into the lumen.
• Functional bowel disorders with constipation predominance: helps normalize stool consistency and frequency.
• Pre‑operative bowel preparation adjunct: can be used to ensure adequate stool softening before surgical procedures.

• Macrogol 3350, a high‑molecular‑weight polyethylene glycol, remains largely non‑absorbed in the gastrointestinal tract. Together with the electrolytes (sodium hydrogen carbonate, potassium chloride, sodium chloride), it creates an osmotic gradient that retains water within the intestinal lumen. The increased intraluminal fluid softens fecal mass and expands the stool volume, stimulating peristalsis and promoting spontaneous evacuation and effectively maintaining normal electrolyte balance.

The most frequently reported reactions with Movicol Go are related to its osmotic activity, while rare events may be more serious.

Common Side Effects

• Abdominal bloating: sensation of fullness or swelling in the abdomen.
• Flatulence: increased intestinal gas production.
• Diarrhoea: loose, watery stools occurring more than usual.
• Nausea: mild feeling of sickness or urge to vomit.
• Stomach cramps: intermittent abdominal pain or cramping.

Serious or Rare Side Effects

• Severe dehydration: marked loss of body fluids requiring medical attention.
• Electrolyte imbalance: abnormal sodium or potassium levels that may cause cardiac or neurological symptoms.
• Allergic reaction: rash, itching, swelling or difficulty breathing.
• Persistent vomiting: ongoing emesis that prevents oral intake.
• Rectal bleeding: unexpected blood in stool indicating possible mucosal injury.

Before prescribing Movicol Go, clinicians should consider several safety aspects to minimise adverse outcomes.

• Assess renal function: impaired kidneys may reduce clearance of electrolytes.
• Review electrolyte status: pre‑existing hyponatraemia or hyperkalaemia requires monitoring.
• Evaluate bowel obstruction: avoid use in complete mechanical obstruction.
• Monitor fluid balance: excessive fluid intake can lead to over‑hydration.
• Use with caution in the elderly: increased susceptibility to dehydration and electrolyte shifts.
• Store at ambient temperature: keep below 25 °C, retain original packaging and protect from moisture.

Movicol Go can affect the absorption or excretion of other medicines; known interactions are grouped by clinical relevance.

Major Interactions (Avoid)

• Digoxin: increased absorption may raise serum levels and risk toxicity.
• Lithium: enhanced lithium reabsorption can lead to lithium toxicity.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, TCAs): concurrent use may increase risk of diarrhoea.
• Antacids containing aluminium or magnesium: may reduce the laxative’s efficacy.
• Oral antibiotics (e.g., tetracyclines, quinolones): osmotic effect can lower antibiotic absorption.
• Diuretics: combined fluid shifts may exacerbate electrolyte disturbances.